Stereotactic Body Radiation Therapy for Melanoma and Renal Cell Carcinoma
Author Information
Author(s): Michelle A Stinauer, Brian D Kavanagh, Tracey E Schefter, Rene Gonzalez, Thomas Flaig, Karl Lewis, William Robinson, Mark Chidel, Michael Glode, David Raben
Primary Institution: University of Colorado Denver, School of Medicine
Hypothesis
Stereotactic body radiation therapy (SBRT) might result in similar high local control rates as previously published on metastases of varying histologies.
Conclusion
An aggressive SBRT regimen with single fraction equivalent dose (SFED) ≥ 45 Gy is effective for controlling metastatic melanoma and renal cell carcinoma.
Supporting Evidence
- The actuarial local control rate was 88% at 18 months.
- Median overall survival for all patients was 24.3 months.
- TCP modeling indicated that to achieve ≥90% 2 yr local control in a 3 fraction regimen, a prescription dose of at least 48 Gy is required.
Takeaway
Doctors used a special type of radiation treatment to help patients with skin and kidney cancer, and it worked really well for many of them.
Methodology
The study reviewed records of patients with metastatic melanoma or RCC treated with SBRT, analyzing local control rates and dose-response relationships.
Potential Biases
Potential selection bias due to the retrospective design and exclusion of patients without follow-up imaging.
Limitations
The study had a small sample size and was retrospective in nature.
Participant Demographics
30 patients (17 males, 13 females) aged 36 to 83, with a median age of 59.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website